source
- Eli Lilly inks $5.9 billion partnership with Stipple Bio to develop precision oncology drugsEli Lilly has announced a partnership with Stipple Bio that could be worth up to $5.9 billion. The collaboration will focus on oncology drug candidates designed to target tumor cells more precisely…
- Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseasesBiogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…